{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:39:52Z","timestamp":1784345992833,"version":"3.55.0"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100020152","name":"Madrigal Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020152","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    This retrospective observational cohort study was conducted using 100% Medicare fee\u2010for\u2010service claims data (10\/01\/2015\u201312\/31\/2021) to characterise risk of incident extrahepatic cancer in patients with non\u2010cirrhotic metabolic dysfunction\u2010associated steatohepatitis (MASH) and for patients with MASH who progressed to more advanced liver disease (compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, liver transplant). For patients with non\u2010cirrhotic MASH, 5\u2010year cumulative incidence was 3.1% for breast cancer, 2.8% for lymphoma\/leukaemia, 2.6% for prostate cancer and 1.4% for lung cancer. The greatest hazard of cancer incidence was observed for bladder (hazard ratio [HR]\u2009=\u20092.36), kidney (HR\u2009=\u20092.15), liver (HR\u2009=\u20092.48) and stomach cancers (HR\u2009=\u20093.38; all\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05), each relative to control individuals without MASH\/metabolic dysfunction\u2010associated steatotic liver disease. Additionally, patients who progressed to advanced liver disease experienced a significantly increased hazard of several extrahepatic cancers. This study provides some of the first evidence on the incidence and risk of extrahepatic cancer among patients with MASH in the United States.\n                  <\/jats:p>","DOI":"10.1111\/liv.70508","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:13:53Z","timestamp":1767863633000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk of Extrahepatic Cancer for Metabolic Dysfunction\u2010Associated Steatohepatitis (\n                    <scp>MASH<\/scp>\n                    ) in the United States Medicare Population"],"prefix":"10.1111","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0263-9384","authenticated-orcid":false,"given":"Yestle","family":"Kim","sequence":"first","affiliation":[{"name":"Madrigal Pharmaceuticals, Inc.  West Conshohocken Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Nunag","sequence":"additional","affiliation":[{"name":"Medicus Economics, LLC  Milton Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0443-0465","authenticated-orcid":false,"given":"Matthew","family":"Davis","sequence":"additional","affiliation":[{"name":"Medicus Economics, LLC  Milton Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6306-3189","authenticated-orcid":false,"given":"Robert","family":"Gish","sequence":"additional","affiliation":[{"name":"Robert G Gish Consultants LLC  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.03.010"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.36469\/001c.92223"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15679"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2021.12.010"},{"key":"e_1_2_13_6_1","volume-title":"MASH Complications","author":"American Liver Foundation"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102021\u2010324191"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16186"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.08.018"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"e_1_2_13_11_1","volume-title":"FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease","author":"US Food and Drug Administration"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010024\u201002979\u20107"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.14218\/jcth.2021.00586"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156066"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2024.12.009"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156014"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2019.11.012"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31726"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15910"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30626"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.70508","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.70508","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.70508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:20:23Z","timestamp":1770909623000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.70508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/liv.70508"],"URL":"https:\/\/doi.org\/10.1111\/liv.70508","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"2025-09-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70508"}}